Hypolipidernic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate)

John P. Morgan, Joseph R. Bianchine, Tah Hsiung Hsu, Simeon Margolis

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


MK-185, an ester structurally related to clofibrate, was given to hypertriglyceridemic patients for 6 week periods in a controlled double-blind crossover trial. Serum triglycerides decreased an average o f 50 per cent during the trial, but little change was noted in serum cholesterol. An average decrease of 30 per cent was noted in the serum uric acid, and 5 patients showed a uricosuric effect of the drug independent of the glomerular filtration rate. Plasma thyroxine (T4) showed a significant increase while patients were taking MK-185. Further studies showed a decrease in protein-bound iodine and T4 by column. An increase in the dialyzable fraction of T4 in vivo suggested a thyroxine-displacing effect from thyroid-binding proteins. This hypothesis was confirmed by in vitro displacement by MK-185 free acid of 131I-labeled T4 bound to thyroid-binding globulin.

Original languageEnglish (US)
Pages (from-to)517-524
Number of pages8
JournalClinical pharmacology and therapeutics
Issue number3
StatePublished - 1971
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Hypolipidernic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate)'. Together they form a unique fingerprint.

Cite this